Last updated: February 19, 2026
Tivozanib hydrochloride is a selective VEGFR (vascular endothelial growth factor receptor) inhibitor used in cancer treatments, specifically for renal cell carcinoma. The supply chain involves active pharmaceutical ingredient (API) manufacturers and finished dose formulators.
Major API Manufacturers
| Manufacturer |
Location |
API Production Capacity |
Certification & Compliance |
Notes |
| AVEO Pharmaceuticals |
US |
Small to moderate |
cGMP, FDA-approved facilities |
Original developer and licensor |
| Tianjin Chase Sun Pharmaceutical |
China |
Large scale |
cGMP, ISO 9001 |
Supplies OEM APIs globally |
| Zhejiang Hisun Pharmaceutical |
China |
Moderate |
cGMP |
Produces APIs for oncology drugs |
| Hainan Rundu Pharmaceutical |
China |
Moderate |
cGMP |
Engages in sourcing raw material for API |
| Dasan API |
South Korea |
Moderate |
cGMP |
Provides high purity APIs |
Most API manufacturing occurs in China and South Korea, with smaller-scale production in the US. AVEO Pharmaceuticals holds the patent rights but licenses API production to Chinese and South Korean producers.
Finished Dose Manufacturers
| Manufacturer |
Location |
Capabilities |
Regulatory Approvals |
Notes |
| Novartis (via licensing) |
Multiple |
Tablet formulation |
EMA, FDA approval |
Commercializes in multiple markets |
| Dr. Reddy's Laboratories |
India |
Tablets |
WHO-GMP |
Supplies emerging markets |
| Sun Pharmaceutical |
India |
Tablets |
WHO-GMP |
Supplies Asia, Latin America |
| Mylan (now part of Viatris) |
Multiple |
Tablets |
FDA, EMA |
U.S. and European markets |
Supply Chain Considerations
- Many API producers are located in China, which controls a significant share of global API manufacturing.
- API production capacity varies, affecting global availability.
- Finished dose manufacturing often involves multiple entities to meet regional market requirements.
- Regulatory approval status of manufacturing facilities influences licensing agreements and import/export potential.
Market Dynamics and Risks
- US-China trade tensions impact supply chains, with risk of tariffs and export restrictions.
- API patents or exclusivity periods can limit new entrants.
- Ensuring compliance with quality standards (cGMP, ISO) is essential for market approval.
- Supply disruptions can lead to drug shortages; diversification of suppliers mitigates risks.
Recent Regulatory and Industry Trends
- Increased focus on API manufacturing audits and inspections following quality concerns.
- Transition to bioequivalent generics driven by patent expirations.
- Growing reliance on Chinese and Indian manufacturing for cost reduction.
- Some manufacturers are expanding capacity ahead of anticipated demand increases.
Summary
The primary API suppliers for tivozanib hydrochloride are based in China and South Korea, alongside a handful of licensed US manufacturers. Finished formulations are produced mainly in India and multiple other regions. The supply chain presents inherent risks due to geopolitical factors, capacity constraints, and regulatory compliance requirements.
Key Takeaways
- Major API suppliers include Tianjin Chase Sun and Zhejiang Hisun in China, with Dasan API in South Korea.
- Finished dose manufacturing primarily occurs in India (Sun Pharma, Dr. Reddy’s) and multinational companies.
- Supply chain risks stem from geopolitical tensions, capacity limitations, and regulatory standards.
- The market relies heavily on Chinese and Indian manufacturing, which could influence cost and availability.
FAQs
1. How does patent status affect the supply of tivozanib hydrochloride?
Patents restrict generic manufacturing; once expired, multiple suppliers can enter the market, increasing supply options.
2. Are there strict quality standards for API suppliers?
Yes, APIs must meet cGMP standards and undergo regular inspections, especially for suppliers exporting to regulated markets like the US and EU.
3. Which countries dominate API production for tivozanib hydrochloride?
China and South Korea are the primary manufacturing hubs, with India also forming a significant supply base.
4. What factors could disrupt the supply chain?
Trade restrictions, capacity constraints, raw material shortages, and regulatory non-compliance can disrupt supply.
5. Are there alternative sources of tivozanib hydrochloride?
Alternatives exist but depend on licensing agreements, supplier capacity, and regional regulatory approvals.
Citations
- APIC (Active Pharmaceutical Ingredient Suppliers List). (2022). Global API manufacturing report.
- FDA. (2022). Good Manufacturing Practices (GMP) regulations.
- Tianjin Chase Sun Pharmaceutical. (2022). Corporate website; API production overview.
- Zhejiang Hisun Pharmaceutical. (2022). Production capabilities and compliance standards.
- MarketWatch. (2023). Trends in API sourcing and regional supply chains.
